4/A: Cumberland Pharmaceuticals Director Corrects Stock Acquisition Report
SEC Filing Amendment
Joseph C. Galante, a director at Cumberland Pharmaceuticals, amends his previous SEC filing to correct the number of shares acquired on March 25, 2024.
Summary
- Joseph C. Galante, a director of Cumberland Pharmaceuticals, filed an amendment to his Form 4 to correct the number of shares acquired on March 25, 2024.
- The original filing on March 26, 2024, incorrectly reported the acquisition of 1,000 shares.
- The corrected filing shows that Galante actually acquired 2,500 shares of common stock at a price of $1.71 per share.
- This correction increases his total direct ownership to 60,856 shares.
Sentiment
Score: 7
Explanation: The document is a routine correction of a regulatory filing. It doesn't inherently indicate positive or negative sentiment, but accuracy in reporting is generally viewed favorably.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The correction ensures accurate information is available to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of stock acquisition |
| 03/26/2024 | Date of original Form 4 filing |
| 01/30/2025 | Date of signature on the amendment |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.